multiple%20myeloma
MULTIPLE MYELOMA

Multiple myeloma is a bone marrow disease characterized by the presence of malignant plasma cells, & abnormal serum &/or urine immunoglobulin secondary to clonal plasma cell expansion.

It accounts for 1-2% of all cancers worldwide & mostly affects patients at ages 65-74 years old.

Patient usually presents with bone pain & nonspecific symptoms, or due to abnormalities in laboratory exams.

 

Supportive Therapy

  • Should be considered for all patients, regardless if eligible for SCT or not

Bone Disease

  • Indications for initiation of treatment for bone disease include:
    • Radiographic evidence of lytic disease (eg lytic bone destruction, spinal compression fracture secondary to osteopenia)
    • Presence of osteopenia without evidence of lytic bone disease
    • Adjunct to pain control in patients with osteolytic disease suffering from pain and those receiving treatment for fractures or impending fractures
    • Presence of osteopenia or osteoporosis in patients with multiple myeloma even if without evidence of lytic bone disease on plain radiograph
    • Presence of MGUS with confirmed osteopenia 
  • Bone-targeting treatment with bisphosphonates or Denosumab for up to 2 years is recommended for all symptomatic multiple myeloma patients receiving therapy 
  • Pamidronate and Zoledronic acid are recommended for patients with bone disease secondary to multiple myeloma (eg osteopenia, osteolytic lesions)
  • Denosumab may be considered as an alternative to bisphosphonates for the prevention of bone disease in multiple myeloma
    • Preferred in patients with renal disease
  • Dental clearance should be obtained prior to initiation of bisphosphonate therapy
  • Monitoring of renal function and symptoms of osteonecrosis of the jaw are recommended during bisphosphonate therapy
  • Patients with intolerable pain due to pathologic fracture or cord compression may opt to undergo low-dose radiation therapy (10-30 Gy in 2.0-3.0 Gy fractions)
  • Surgical management via kyphoplasty or vertebroplasty may also be considered for symptomatic vertebral compression fractures

Anemia

  • Decreased hemoglobin levels of <10 g/dL may be treated with recombinant human erythropoietin and Darbepoietin alfa
  • Red blood cell transfusion may also be considered in patients with abrupt need for increased Hgb levels
  • Patients who develop severe granulocytopenia after chemotherapy may be considered for granulocyte-stimulating factor (G-CSF) therapy

Hypercalcemia

  • Adequate hydration, bisphosphonates (eg Zoledronic acid, Pamidronate, Ibandronate), Denosumab, corticosteroids, and/or Calcitonin may be given to patients with increased bone resorption secondary to bone disease in myeloma

Renal Impairment

  • Bortezomib-based regimens (eg Bortezomib plus Dexamethasone with or without Thalidomide, Doxorubicin, or Cyclophosphamide) is recommended for patients with renal failure

Venous Thromboembolism (VTE)

  • Hyperviscosity and hypercoagulability due to multiple myeloma lead to increased risk for thrombosis formation
  • Multiple myeloma patients are at increased risk for thrombotic events especially during chemotherapy with Doxorubicin and immunomodulatory drugs (IMiDs) (eg Lenalidomide, Pomalidomide, Thalidomide) with Dexamethasone
  • Aspirin is recommended for patients with low risk for VTE receiving IMiD-based therapy
  • Low molecular weight heparin or Warfarin is recommended for patients at increased risk for thrombosis

Infection/Reactivation

  • Prevention of infectious complications by administration of IVIg, anti-infective prophylaxis, and vaccinations are recommended
    • Vaccination for influenza and S pneumoniae is recommended
    • IV immunoglobulin replacement therapy may be considered for patients with recurrent, severe infection despite prophylactic antibiotic therapy
    • Prophylaxis against Pneumocystis jiroveci pneumonia (PJP) and fungal infection should be considered in patients being given high-dose regimens
    • Patients being treated with protease inhibitors especially Bortezomib, Carfilzomib, Isatuximab-irfc, Ixazomib, Daratumumab and Elotuzumab or undergoing ASCT or allo-SCT should receive prophylaxis for herpes zoster (eg Acyclovir, Valaciclovir)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
10 Jan 2021
Regular practice of yoga postures confers benefits for glucose control, oxidative stress, inflammatory response, and sleep quality in patients with type 2 diabetes, a study has found.
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
Pearl Toh, 26 Nov 2020
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.